(4) Most of the existing models were specifically designed to predict the GPV carrier risk in BRCA1/2 genes and thus cannot be readily used to assess the risk for other breast cancer predisposition loci, which are also important for personalized healthcare decisions. This evidence concerns the gene BRCA1 and breast carcinoma.